NLE Renal & Urinary Nursing — UTI & Inflammatory Renal DisordersStudy Notes

A urinary tract infection (UTI) is the presence of pathogenic microorganisms in the normally sterile urinary tract. The majority of UTIs ascend from the perineum through the urethra into the bladder and, if untreated, into the upper urinary tract. Escherichia coli (E. coli) accounts for approximately 80–85% of uncomplicated UTIs; other common pathogens include Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus saprophyticus (especially in young women). RISK FACTORS FOR UTI: • Female sex (anatomically shorter urethra; proximity of urethral opening to the anus) • Sexual activity and pregnancy • Indwelling urinary catheters (especially prolonged use—a major nosocomial risk) • Urinary retention and obstruction • Diabetes mellitus and immunosuppression • Urinary stasis (from incomplete emptying or anatomical anomalies) • History of previous UTI (increases recurrence risk) CLASSIFICATION: Lower UTI: Cystitis (bladder inflammation) and urethritis (urethra inflammation); these are typically acute, uncomplicated infections with localized symptoms. Upper UTI: Pyelonephritis (renal pelvis and parenchymal involvement); this represents systemic infection and is the ascending complication of untreated lower UTI. CLINICAL MANIFESTATIONS OF LOWER UTI (CYSTITIS): • Dysuria: burning, painful sensation during urination (often the earliest and most bothersome symptom) • Urinary frequency: need to void more than every 2 hours during the day and 1–2 times at night • Urinary urgency: sudden, compelling need to urinate • Suprapubic pain, pressure, or tenderness (just above the pubic symphysis) • Hematuria: presence of blood in urine (gross or microscopic); urine may appear cloudy or dark • Foul-smelling urine: characteristic "fishy" or ammonia-like odor • Absence of fever in uncomplicated cystitis (this distinguishes it from pyelonephritis) ATYPICAL PRESENTATION IN OLDER ADULTS (High-Yield NLE Point): In geriatric patients (65+ years), classic dysuria and urinary symptoms may be COMPLETELY ABSENT. Instead, nurses must recognize these atypical presentations as possible UTI: • Acute confusion or delirium (new-onset mental status changes) • Urinary incontinence in a previously continent patient • Falls or functional decline • Generalized weakness or fatigue • Anorexia or decreased oral intake This atypical presentation is a critical safety issue. Many older adults have asymptomatic bacteriuria; treatment guidelines recommend screening and treating pregnant women and those undergoing urologic procedures, but not asymptomatic non-pregnant, non-urologic patients (to avoid unnecessary antibiotic resistance). However, SYMPTOMATIC UTI in older adults (however it presents) demands treatment. PHARMACAL PATHOPHYSIOLOGY NOTE: The inflammatory response to bacterial colonization damages the bladder mucosa, triggering irritation and the symptoms above. The urine becomes alkaline and turbid due to bacterial metabolism and host inflammatory cells (WBCs, RBCs, epithelial cells).

URINALYSIS (First-Line Screening): A urinalysis provides presumptive evidence of UTI and should be collected BEFORE starting antibiotics (NLE emphasis): Positive findings in UTI: • Leukocyte esterase: positive (enzyme released by WBCs; nearly 90% sensitive for bacteriuria in symptomatic patients) • Nitrites: positive (produced by gram-negative bacteria metabolizing dietary nitrates; highly specific for UTI but less sensitive) • Pyuria: white blood cells >5/high-power field (hpf); indicates inflammation • Bacteriuria: visible bacteria on microscopy • Hematuria: RBCs present (usually from mucosal trauma; not always present) • Proteinuria: small amount may be present (large amounts suggest upper UTI or glomerular disease) • pH: usually alkaline in UTI (bacterial metabolism raises pH) • Appearance: cloudy, turbid, or dark; may have sediment IMPORTANT: Negative leukocyte esterase and nitrites do NOT rule out UTI (10% may be falsely negative); clinical symptoms guide further testing. Urine Culture & Sensitivity (Gold Standard): The only way to definitively confirm UTI, identify the causative organism, and determine antibiotic susceptibility. Collection MUST be done BEFORE antibiotic initiation. Significant colony counts (by collection method): • Clean-catch midstream: ≥100,000 (10⁵) colony-forming units per mL (CFU/mL) is traditionally significant for symptomatic patients; however, **some labs now recognize ≥10,000 CFU/mL as significant in symptomatic women**. (This reflects lower bacterial counts in early infection.) • Straight catheterization: ≥100 CFU/mL is significant • Suprapubic aspiration: ANY growth is significant (the specimen is sterile) In men, ANY growth in a properly collected midstream specimen is considered significant (lower rates of asymptomatic bacteriuria). NURSING COLLECTION TECHNIQUE FOR CLEAN-CATCH MIDSTREAM SPECIMEN: 1. Educate the patient on the purpose and technique BEFORE collection. 2. For female patients: - Instruct to sit on toilet or use a clean bedpan. - Cleanse the perineum: using sterile gauze with cleansing solution (such as povidone-iodine or a single-use povidone packet), wipe from anterior (pubic area) to posterior (toward anus) in a front-to-back motion. Use a separate gauze for each wipe. This prevents fecal contamination. - Spread labia minora with non-sterile hand; begin urination into the toilet/bedpan. - Mid-stream (after 15–30 mL has passed), catch approximately 30–50 mL in a STERILE container without contaminating the rim. - Complete urination into the toilet. 3. For male patients: - Retract the foreskin (if present). - Cleanse the meatus with sterile gauze in a circular motion (from center outward). - Begin urination into the toilet; collect midstream into a sterile container. 4. Seal the container, label with patient name, date, time, and collection method. 5. Keep the specimen at room temperature or refrigerate (per lab protocol) if transport is delayed; do NOT freeze. Other Culture Methods: • Straight catheterization: used when patient cannot void or provide a clean-catch specimen (e.g., women with severe obesity, urinary retention). Any growth is significant. • Suprapubic aspiration: gold standard for obtaining uncontaminated urine; used in neonates or select complicated cases. Procedure: sterile needle inserted above the pubic symphysis into the bladder under ultrasound guidance. ANY bacterial growth is diagnostic of UTI. ADDITIONAL DIAGNOSTIC TESTS: • Renal ultrasound or CT: indicated if recurrent UTI, to rule out obstruction, anatomic anomalies, or abscess. • Voiding cystourethrogram (VCUG): used in children to assess for vesicoureteral reflux (VUR) after a febrile UTI. • Cystoscopy: if recurrent sterile pyuria or hematuria is present (to rule out malignancy or other pathology).

NURSING DIAGNOSES (NANDA-I) FOR UTI: 1. Dysuria related to urinary tract infection, as evidenced by patient report of burning sensation during urination. 2. Impaired urinary elimination related to irritation of urinary tract, as evidenced by frequency, urgency, and nocturia. 3. Acute pain related to inflammatory response in the bladder mucosa, as evidenced by suprapubic tenderness. 4. Risk for ascent of infection (upper UTI/pyelonephritis) related to untreated or incompletely treated lower UTI. 5. Deficient knowledge related to UTI prevention, as evidenced by patient asking, "How do I prevent this from happening again?" PRIORITY NURSING INTERVENTIONS (According to Maslow's Hierarchy): Level 1: Physiologic Needs—Pain & Comfort • Administer urinary analgesics (e.g., phenazopyridine 100–200 mg three times daily after meals) as prescribed. CRITICAL EDUCATION: Phenazopyridine causes orange/red discoloration of urine and tears—this is harmless and expected. It RELIEVES SYMPTOMS ONLY and is NOT an antibiotic. It should be used for no more than 2 days (to avoid hepatotoxicity). The underlying infection is treated by antibiotics. • Assess pain using a pain scale; provide non-pharmacologic comfort measures: sitz baths (warm water immersion for 10–15 minutes), heating pad to suprapubic area, and relaxation techniques. • Monitor I&O; encourage frequent voiding to prevent stasis. Level 2: Safety—Infection Control & Antibiotic Therapy • Administer antibiotics exactly as prescribed; the selection depends on the organism, local resistance patterns, and patient factors: - **First-line for uncomplicated UTI in non-pregnant women**: Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg twice daily for 3 days (short course is as effective as longer courses and reduces resistance) - **Nitrofurantoin**: 100 mg twice daily for 5 days (not effective for pyelonephritis; primarily lower UTI) - **Fosfomycin**: single dose 3 g (emerging first-line; excellent for resistant organisms) - **Fluoroquinolones (ciprofloxacin, levofloxacin)**: used for resistant organisms or complicated UTI; 500 mg twice daily for 7 days (or based on culture sensitivity) - **Beta-lactams (amoxicillin-clavulanate, cephalosporins)**: if allergy to sulfonamides or resistance; longer courses (7–10 days) • PATIENT EDUCATION—Most Critical Point: The patient MUST complete the FULL course of antibiotics (even after symptoms resolve in 2–3 days). Incomplete courses lead to: - Relapse (same organism recurs) - Development of antibiotic-resistant strains - Progression to upper UTI/pyelonephritis - Write a specific reminder: "Take all antibiotics until gone, even if you feel better." • Monitor for adverse effects: allergy/hypersensitivity reactions (rash, anaphylaxis), GI disturbances (nausea, diarrhea—Clostridium difficile with fluoroquinolones), photosensitivity, and tendon rupture risk with fluoroquinolones in older adults. • In pregnancy: treat asymptomatic bacteriuria to prevent pyelonephritis and preterm labor. Safe agents include nitrofurantoin, amoxicillin, cephalosporins. AVOID trimethoprim (especially first trimester—risk of neural tube defects), fluoroquinolones, and tetracyclines. Level 3: Health Promotion—Hydration & Flushing • Encourage increased fluid intake: target 2–3 L/day (approximately 8–10 glasses of water) unless contraindicated (e.g., heart failure, renal disease requiring fluid restriction). Higher fluid intake increases urine output, dilutes urine concentration, and promotes mechanical "flushing" of bacteria from the tract. • Assess for adequate hydration: pale, dilute urine indicates good hydration. • Avoid bladder irritants: caffeine, alcohol, spicy foods, carbonated beverages, and artificial sweeteners can irritate the bladder and worsen symptoms. • Ensure regular emptying: advise patient to void every 2–3 hours during the day and not to "hold" urine. LEVEL 4: Self-Actualization—Patient Education & Prevention This is perhaps THE most important nursing intervention for UTI because **prevention is the best treatment** and recurrence is common (20% of women with UTI experience recurrence within 6 months): PERSONAL HYGIENE & VOIDING HABITS: • **Front-to-back wiping**: After urination or defecation, wipe from anterior (urethra) to posterior (anus) using a separate gauze/tissue for each wipe. This prevents fecal (anal) flora from contaminating the urethra. Teach this to all female patients (and caregivers of children/older adults). • **Void after intercourse**: Sexual activity can introduce bacteria into the urethra. Voiding within 15 minutes after intercourse flushes the urethra mechanically. • **Regular, complete emptying**: Do not delay urination; empty the bladder fully each time. • **Avoid irritants**: No douching, bubble baths, perfumed hygiene products, or scented toilet paper (these disrupt normal flora and irritate the mucosa). • **Wear breathable underwear**: Cotton underwear allows better air circulation and moisture wicking compared to synthetic fabrics, which trap moisture and promote bacterial growth. DIETARY & LIFESTYLE MEASURES: • **Adequate hydration**: Emphasize that water intake is the single most important preventive measure. Some evidence supports cranberry juice or cranberry supplements (proanthocyanidins may prevent bacterial adherence to uroepithelial cells), though the evidence is mixed; it is not a substitute for hydration and antibiotics. • **Avoid constipation**: Adequate fiber intake and regular bowel movements prevent fecal stasis and reduce perineal contamination. • **Maintain normal weight**: Obesity increases infection risk. OTHER STRATEGIES: • **Prophylactic antibiotics**: For women with recurrent UTI (≥3 in a year), options include: - Continuous prophylaxis: low-dose TMP-SMX or nitrofurantoin nightly for 6–12 months - Post-coital prophylaxis: single dose of TMP-SMX or nitrofurantoin after intercourse (effective for sexually active women) - Self-initiated therapy: patient begins a short course (3-day regimen) at the first sign of symptoms • **Estrogen therapy**: In postmenopausal women, topical vaginal estrogen may reduce recurrent UTI by promoting normal vaginal flora. MONITORING & FOLLOW-UP: • Assess symptom resolution: dysuria, frequency, and urgency should improve within 24–48 hours of antibiotic initiation; if not, consider resistance or alternative diagnosis. • For complicated UTI or pyelonephritis, repeat urine culture 1–2 weeks after completing antibiotics (test of cure) to confirm eradication, especially in men and pregnant women. • For uncomplicated lower UTI in non-pregnant women, test of cure is NOT routinely needed if symptoms resolve. • Educate on signs of worsening/upper UTI: fever, flank pain, nausea/vomiting, or decreased urine output—report immediately.

PATHOPHYSIOLOGY & RISK FACTORS: Pyelonephritis is an **acute infection and inflammation of the renal pelvis and renal parenchyma**, representing the **ascending (upper) complication of UTI**. It results from bacterial seeding from the lower urinary tract, usually via the ureter. Risk factors are largely the same as for lower UTI, but factors that promote stasis or obstruction are particularly important: • Untreated or inadequately treated lower UTI • Anatomic obstructions: urolithiasis, tumors, strictures • Vesicoureteral reflux (especially in children—can cause recurrent pyelonephritis and renal scarring) • Neurogenic bladder (spinal cord injury, multiple sclerosis) • Pregnancy (physiologic ureteral dilation increases risk; pyelonephritis occurs in ~2% of pregnant UTI cases) • Indwelling catheters • Diabetes and immunosuppression • Male urinary tract infection in men (considered "complicated" and warrants upper UTI evaluation) CLINICAL MANIFESTATIONS: Pyelonephritis presents with ALL the lower-UTI symptoms **PLUS systemic illness**: LOWER UTI SYMPTOMS (may or may not be present): • Dysuria • Frequency, urgency • Suprapubic discomfort UPPER UTI & SYSTEMIC SYMPTOMS (the distinguishing features—"PLUS" the above): • **HIGH FEVER**: typically ≥38.5°C (101.3°F) or higher; often abrupt onset • **CHILLS and rigors**: muscle shaking with fever • **Flank pain**: unilateral pain in the area of the kidneys (just below the rib cage on one side) • **Costovertebral angle (CVA) tenderness**: pain elicited when the nurse percusses (gently taps) over the costovertebral angle (the angle formed by the lower rib and lateral spine). This is a KEY CLINICAL SIGN of kidney involvement. Perform this assessment: - Position the patient sitting upright, leaning forward slightly, or prone. - Place the palm of one hand flat over the CVA (kidney area). - Gently tap the back of the hand with the fist of the other hand. - Positive response: patient reports tenderness or discomfort (not just a percussion sound). • Nausea and vomiting (from systemic toxicity) • General malaise, weakness • Headache, myalgia • Hematuria may be present • Bacteremia possible in severe cases (positive blood cultures in ~20–30%) COMPARISON: Lower UTI (Cystitis) vs. Upper UTI (Pyelonephritis) | Feature | Cystitis | Pyelonephritis | |---------|----------|----------------| | Fever | None or low-grade | HIGH (≥38.5°C) | | Chills/rigors | No | Yes | | Flank/back pain | No | YES (unilateral) | | CVA tenderness | Absent | PRESENT | | Nausea/vomiting | No | Yes | | Dysuria | Yes | May or may not be present | | Urgency/frequency | Yes | May or may not be present | | Systemic illness | No | YES—marked | DIAGNOSTIC FINDINGS: • **Urinalysis**: similar to UTI (leukocyte esterase+, nitrites+, pyuria, bacteriuria, hematuria) • **Urine culture**: OBTAIN BEFORE ANTIBIOTICS; often shows higher bacterial counts (>100,000 CFU/mL); identifies the organism and susceptibility. • **Blood culture**: should be drawn in hospitalized patients with fever/sepsis; positive in ~20–30% of cases; helps guide IV antibiotic selection. • **Complete blood count (CBC)**: leukocytosis (WBC >11,000/μL) with left shift (increased bands/immature neutrophils)—marker of acute infection. • **Comprehensive metabolic panel (CMP)**: may show elevated creatinine and BUN if infection is severe or kidney function is compromised; electrolyte abnormalities if dehydrated or vomiting. • **Imaging** (for complicated/recurrent pyelonephritis): - Renal ultrasound: assesses for obstruction, abscess, or anatomic anomalies. - CT abdomen/pelvis: gold standard for detecting complications (abscess, scarring, obstruction). - VCUG (in children): detects vesicoureteral reflux. NURSING DIAGNOSES & MANAGEMENT: NANDA-I NURSING DIAGNOSES: 1. **Hyperthermia** related to systemic infection, as evidenced by fever ≥38.5°C, chills, and malaise. 2. **Acute pain** related to renal inflammation, as evidenced by flank pain, CVA tenderness, and patient report. 3. **Risk for dehydration** related to fever, vomiting, and increased metabolic demands. 4. **Risk for sepsis/urosepsis** related to bacterial spread from the kidney into the bloodstream. 5. **Impaired urinary elimination** related to urinary tract infection. 6. **Deficient knowledge** related to prevention of recurrent pyelonephritis. PRIORITY NURSING INTERVENTIONS (Maslow-Based): **Level 1: Physiologic—Infection Control, Fever Management, Fluid Balance** Antimicrobial Therapy: • **Empiric IV antibiotics** are initiated in hospitalized/severely ill patients BEFORE culture results (broad-spectrum coverage): - **Third-generation cephalosporin** (e.g., ceftriaxone 1–2 g IV daily) + **gentamicin** 5–7 mg/kg IV daily (for gram-negative coverage) OR - **Fluoroquinolone** (e.g., ciprofloxacin 400 mg IV twice daily or levofloxacin 750 mg IV daily) OR - **Beta-lactam/beta-lactamase inhibitor** (e.g., piperacillin-tazobactam 3.375–4.5 g IV every 6–8 hours) • **Oral antibiotics** for mild-to-moderate outpatient pyelonephritis (if tolerated and reliable follow-up): - Fluoroquinolone: ciprofloxacin 500–750 mg PO twice daily OR levofloxacin 750 mg PO daily for 7–14 days - Trimethoprim-sulfamethoxazole (if susceptible): double-strength twice daily for 14 days - Cephalosporin: cephalexin 500 mg PO four times daily for 14 days • **Duration**: typically 14 days (longer than simple cystitis) to ensure eradication from the kidney parenchyma. • **Obtain cultures BEFORE starting antibiotics**; adjust therapy based on susceptibility. Fever Management: • Monitor core body temperature every 2–4 hours (or continuous monitoring if high-risk); report fever trends. • **Antipyretics**: acetaminophen 500–650 mg PO/IV every 4–6 hours or ibuprofen 400–600 mg PO every 6 hours. NSAIDs may also help with flank pain (dual benefit). • **Environmental measures**: light clothing, tepid sponging (NOT ice water, which causes shivering and increases metabolic rate), fan, and cool environment. • Watch for febrile seizures in young children; cool aggressively. Fluid & Electrolyte Management: • **Increase fluid intake** (same as UTI: 2–3 L/day if oral intake tolerated) to promote urine output and "flush" bacteria; monitor I&O carefully. • **IV hydration** in hospitalized patients: normal saline or balanced crystalloid solution (e.g., Lactated Ringer's) to maintain urine output ≥200 mL/4 hours and correct dehydration from fever/vomiting. • Monitor electrolytes (Na+, K+, Cl–, HCO3–) especially if vomiting is present; replace losses. • Assess for dehydration: increased BUN/creatinine ratio, decreased urine output, orthostatic hypotension. Pain Management: • Assess pain using a pain scale; note location (flank) and radiation. • Analgesics: opioids (e.g., morphine 2–4 mg IV every 2–4 hours) for severe pain; NSAIDs for moderate pain and fever (dual benefit); urinary analgesics (phenazopyridine) may help if dysuria is bothersome. • Non-pharmacologic: position changes, heating pad to flank, relaxation. **Level 2: Safety—Infection Prevention, Monitoring for Complications** • **Infection control**: standard precautions; ensure proper catheter care if Foley is in place (maintain sterile, patent system; minimize duration). • **Monitor for sepsis/urosepsis** (a medical emergency): signs include **fever, hypotension (SBP <90 mmHg), tachycardia (HR >90), tachypnea (RR >20), altered mental status, and lactate elevation**. If suspected, escalate care immediately (ICU consideration, rapid sepsis protocol). • **Reassess kidney function**: monitor creatinine and BUN trends; if they worsen despite antibiotics, consider obstruction or abscess (imaging needed). • **Indwelling catheter**: if present, consider removal once patient can void; prolonged catheterization perpetuates infection. **Level 3: Health Restoration—Symptom Resolution, Return to Activity** • Expect fever to resolve within 48–72 hours of appropriate antibiotics; if fever persists, consider: - Incorrect diagnosis or resistant organism - Obstruction (e.g., stone) preventing antibiotic delivery - Abscess formation (ultrasound or CT needed) - Sepsis (worsening clinical picture) • **Activity**: bed rest during acute illness (reduce metabolic demands); gradually increase as fever resolves and patient feels better. **Level 4: Health Promotion—Patient Education & Prevention of Recurrence** • Reinforce all UTI prevention measures (front-to-back wiping, post-coital voiding, hydration, etc.) because pyelonephritis is a serious complication that warrants aggressive prevention. • Educate on **red flags requiring immediate medical attention**: **fever that returns or persists, flank pain worsening, nausea/vomiting, decreased urine output, or confusion** (signs of sepsis or obstruction). • Discuss importance of **completing the full 14-day antibiotic course** (longer than simple UTI). • In recurrent pyelonephritis, evaluate for underlying anatomic problems or reflux; recommend follow-up imaging. COMPLICATIONS OF PYELONEPHRITIS: • **Urosepsis**: bacterial spillover into the bloodstream, causing septic shock (fever, hypotension, organ dysfunction); a medical emergency requiring ICU-level care. • **Renal abscess**: collection of pus in the kidney; diagnosis by ultrasound or CT; may require percutaneous drainage or open surgery. • **Renal scarring**: can occur after severe or recurrent pyelonephritis, especially in children and those with reflux; leads to decreased kidney function and chronic kidney disease if extensive. • **Acute kidney injury**: in severe infection or sepsis; usually reversible with treatment of the underlying infection and fluid resuscitation. • **Pregnancy complications**: pyelonephritis in pregnancy increases risk of preterm labor and preterm delivery; aggressive treatment is essential.

PATHOPHYSIOLOGY: Glomerulonephritis (GN) is an **inflammation of the renal glomeruli** (the kidney's filtering units) that damages the glomerular basement membrane and reduces the glomerular filtration rate (GFR). The most classic form is **acute post-streptococcal glomerulonephritis (APSGN)**, an **immune-complex-mediated** reaction: MECHANISM OF APSGN: 1. **Infection**: Group A beta-hemolytic streptococcal infection occurs (usually throat/pharyngitis; less commonly skin/impetigo). 2. **Immune response**: The host mounts an antibody response to streptococcal antigens. However, certain streptococcal antigens cross-react with kidney antigens (molecular mimicry). 3. **Immune-complex formation**: Antibody-antigen complexes form in the bloodstream and deposit in the **glomerular basement membrane (GBM)** and **glomerular capillaries**. 4. **Complement activation**: Deposited complexes activate the complement cascade (especially C3), triggering inflammation. 5. **Glomerular damage**: Inflammation damages the filtration barrier, making it permeable to RBCs, protein, and sometimes WBCs. The GFR decreases (oliguria), and waste products accumulate. TIMING: APSGN typically develops **1–2 weeks after the acute streptococcal infection** (range: 1–3 weeks for throat infection; up to 6 weeks for skin infection). By the time GN manifests, the strep infection may have resolved, making the history crucial. RISK FACTORS: • Prior streptococcal infection (strep throat, impetigo) • Young children (most common in ages 3–12) and older adults can be affected • Overcrowded living conditions, poor hygiene • Malnutrition • Non-compliant antibiotic use for strep infection CLINICAL MANIFESTATIONS—THE "NEPHRITIC" PICTURE: The classic presentation of APSGN (and other GN) is the **nephritic syndrome**, characterized by: **GROSS HEMATURIA — THE HALLMARK & MOST STRIKING SIGN: • The urine is **cola-colored, tea-colored, or smoky brown** due to the presence of RBCs and RBC casts. • This is highly visible and alarming to patients/families; they often report "my child's urine turned brown overnight." • Hematuria can be GROSS (visible to the naked eye) or microscopic (RBCs found only on UA). HYPERTENSION: • Present in 50–60% of children with APSGN; more common in adults. • Caused by **fluid retention** (decreased GFR → sodium and water retention) and **activation of the renin-angiotensin-aldosterone system (RAAS)**. • May be mild (slightly elevated) or significant (risk of hypertensive complications). • **Critical**: Hypertension in GN can lead to **hypertensive encephalopathy** (confusion, seizures, cerebral edema)—a medical emergency. PERIORBITAL AND FACIAL EDEMA: • **Periorbital edema** (puffiness around the eyes) is the most characteristic edema of GN and is typically **worse in the morning** after lying flat overnight (fluid shifts to dependent areas during sleep). • **Facial edema** may also be present; less dependent edema of the lower extremities than in nephrotic syndrome (because the nephritic picture is primarily hematuria + hypertension, not massive protein loss). • Edema is mild-to-moderate in APSGN and often improves as the inflammation resolves. OLIGURIA: • Urine output is **decreased (<0.5 mL/kg/hour in children; <400–500 mL/day in adults)** due to reduced GFR. • Not present in all cases (some have normal urine output); when present, indicates more severe disease. PROTEINURIA: • Mild-to-moderate proteinuria is present (typically <3.5 g/day, distinguishing GN from nephrotic syndrome, which has massive proteinuria >3.5 g/day). • RBCs, RBC casts, and WBCs are present on microscopy (pyuria may reflect inflammation, not infection). SYSTEMIC/CONSTITUTIONAL SYMPTOMS: • Malaise, fatigue, general unwell feeling • Mild fever (usually low-grade; high fever suggests infection, not just GN) • Flank or back ache • Headache (especially if hypertensive) • Nausea and loss of appetite LABORATORY FINDINGS: • **Elevated BUN and creatinine**: reflects decreased GFR; usually mild-to-moderate elevation (BUN may rise faster than creatinine) • **Low serum complement (C3)**: due to consumption in the immune-complex reaction; LOW C3 is the hallmark immunologic finding in APSGN and helps confirm the diagnosis. C4 is usually normal (helps differentiate from other GN types like SLE). C3 normalizes within 6–8 weeks as inflammation resolves. • **Elevated antistreptolysin-O (ASO) titer**: evidence of recent group A streptococcal infection; titer >250 Todd units is considered elevated. May still be rising early in GN or declining if infection was weeks prior. • **Elevated anti-DNase B titer**: another marker of recent strep (especially skin infection/impetigo). • **Normal complement (C4) and other immunologic markers**: helps differentiate APSGN from lupus nephritis or other GN types. URINALYSIS (KEY DIAGNOSTIC TEST): • **Hematuria**: RBCs present (microscopic or gross) • **RBC casts**: highly specific for GN (casts are cylindrical molds of the renal tubule; RBC casts indicate RBCs were in the tubule, meaning glomerular bleeding) • **Proteinuria**: mild-to-moderate (not massive) • **Pyuria**: may be present (inflammation, not infection) • **Bacteria**: ABSENT (GN is not an infection) KIDNEY BIOPSY: • Not routinely performed for APSGN (diagnosis is usually clinical + serologic). • **Light microscopy**: shows endocapillary proliferation ("starry sky" appearance), glomerular cellularity, mesangial proliferation. • **Immunofluorescence**: shows **granular IgG, IgA, and C3 deposits** on the glomerular basement membrane (subepithelial, "humps")—pathognomonic for APSGN. • Biopsy is indicated if diagnosis is uncertain or if GN is rapidly progressive (RPGN features). NURSING DIAGNOSES (NANDA-I): 1. **Excess fluid volume** related to decreased GFR and sodium/water retention, as evidenced by periorbital edema, hypertension, and oliguria. 2. **Risk for hypertensive crisis** related to fluid retention and RAAS activation. 3. **Imbalanced nutrition: less than body requirements** related to decreased appetite and nausea. 4. **Risk for acute kidney injury** related to reduced GFR and glomerular damage. 5. **Deficient knowledge** related to GN pathophysiology and management. PRIORITY NURSING INTERVENTIONS: **LEVEL 1: PHYSIOLOGIC NEEDS—BLOOD PRESSURE & FLUID MANAGEMENT** **Blood Pressure Monitoring (CRITICAL):** • Monitor BP **at least twice daily** (more frequently if elevated); in acute phase, consider continuous monitoring. • Compare to patient's baseline; any elevation is significant (especially in children, in whom GN typically causes more prominent hypertension). • **Report hypertension immediately to the physician**; hypertensive encephalopathy is a medical emergency. • **Antihypertensive therapy** (if BP is elevated): - **ACE inhibitors** (e.g., lisinopril) or **ARBs** (e.g., losartan): first-line; also provide renal protection (reduce proteinuria and slow progression) - **Diuretics** (e.g., furosemide/lasix 20–40 mg IV/PO): help reduce fluid overload and decrease BP - **Calcium-channel blockers** (e.g., amlodipine): alternative - **Avoid NSAIDs**: can worsen renal function; avoid in acute GN **Fluid & Sodium Restriction (During Edema/Oliguria):** • **Fluid restriction**: typically 400–800 mL/day (or based on urine output + insensible losses) during acute oliguria; liberalize as GFR recovers and urine output increases. • **Sodium restriction**: keep to 1–2 g/day (strict "no added salt" diet) during the edematous/oliguric phase to reduce fluid retention. As inflammation resolves and diuresis begins, restriction can be relaxed. • Monitor **daily weight at the same time of day** (morning, after urination, before food); a sudden 0.5–1 kg gain indicates fluid retention; gains >1 kg/day warrant increased diuretics or further fluid restriction. • Maintain **accurate I&O records**: measure all oral intake and urine output (weight changes on a gram scale if available); if oliguria is present, fluid intake should match measured urine output plus insensible losses (~500 mL/day). • Assess for **signs of fluid overload**: worsening edema, dyspnea, orthopnea, crackles on lung auscultation, elevated JVP—these suggest progression to heart failure; notify physician immediately. **Protein Restriction (if BUN is markedly elevated):** • If BUN is **significantly elevated (>50 mg/dL) due to oliguria and decreased GFR**, restrict dietary protein to **0.8 g/kg/day** (or as prescribed) to reduce further urea production and prevent uremia. • Once GFR recovers and BUN normalizes, protein restriction is no longer needed. • Do NOT restrict protein if BUN is normal; the kidney needs adequate protein for recovery. **LEVEL 2: SAFETY—PREVENTION OF COMPLICATIONS** **Infection Prevention:** • Treat any residual streptococcal infection: **penicillin V 250 mg PO four times daily for 10 days** (or IM benzathine penicillin G 1.2 million units for compliance). This does NOT reverse the GN but prevents spread of strep and recurrent infection. • Watch for signs of infection (fever, new symptoms); strep infection can recur and trigger another cycle of GN. **Monitoring for Acute Kidney Injury:** • Track **BUN, creatinine, and estimated GFR (eGFR)** trends; most patients show improvement within 1–2 weeks as inflammation resolves. • If BUN/creatinine **worsen or plateau** despite treatment (especially in adults), suspect **rapidly progressive GN (RPGN)** or another complication; imaging and possible biopsy may be needed. • Monitor **serum electrolytes** (K+, Na+, Cl–, HCO3–, phosphate, calcium); hyperkalemia (elevated K+) can occur with reduced GFR and requires monitoring and treatment. **Monitoring Complement Levels:** • C3 levels are drawn at diagnosis and rechecked in 6–8 weeks; normalization of C3 indicates resolution of inflammation and supports favorable prognosis. • Persistent low C3 at 8 weeks suggests other diagnoses (e.g., membranoproliferative GN, lupus) requiring further investigation. **LEVEL 3: HEALTH RESTORATION** **Expect Recovery Timeline:** • Most children with APSGN have **excellent long-term prognosis**: 95% recover completely with normal kidney function. • Adults have a **more guarded prognosis**: 10–20% progress to chronic GN or end-stage renal disease (especially those with oliguria, severe hypertension, or delayed diagnosis). • Expect clinical improvement within **1–2 weeks** of onset: hematuria clears (urine returns to normal color), BP normalizes, edema resolves, urine output increases. • Hematuria may take **months to fully clear** on repeat urinalysis, but gross hematuria should resolve quickly. **Activity:** • **Bed rest during acute phase** (oliguria, hypertension, systemic illness) to reduce metabolic demands. • **Gradually increase activity** as fever resolves, BP normalizes, and urine output increases. • **Avoid strenuous exercise** during recovery (risk of hematuria recurrence); normal activities can resume once GN resolves. **LEVEL 4: HEALTH PROMOTION—PATIENT & FAMILY EDUCATION** **Dietary Counseling:** • Explain sodium and fluid restriction (if applicable): "Salt increases water retention, which raises blood pressure. We're limiting salt and fluids temporarily while your kidneys heal." • Explain protein restriction (if BUN is high): "Protein makes waste that your kidneys have trouble clearing right now. We'll limit it temporarily." • Provide a list of allowed and restricted foods; involve dietitian if available. **Activity Restrictions:** • Explain why bed rest is needed in the acute phase (to help swelling go down and blood pressure come down). • Clarify that activity restrictions are **temporary**; most patients return to normal activity within weeks as GN resolves. • Counsel on **avoiding strenuous exercise** (sports, heavy lifting) for at least 4–6 weeks or until hematuria has completely cleared and BP is normal; hematuria can recur with exertion. **Prognosis & Long-Term Outlook:** • Reassure that APSGN is **usually self-limited**; most children recover completely, and many adults also have good outcomes. • Explain that **complete recovery of kidney function is expected in most cases**, especially if treatment is initiated early. • Advise on **warning signs requiring immediate follow-up**: persistent or increasing hematuria, worsening edema, new-onset hypertension, decreased urine output, fatigue, or signs of infection. **Follow-Up Care:** • Schedule **repeat urinalysis** at 2 weeks, 6 weeks, and 3 months to track clearance of hematuria and proteinuria. • Check **BP at each visit**; most normalize within weeks. • Recheck **C3 levels** at 6–8 weeks (should normalize); persistent low C3 suggests different diagnosis. • If hematuria or proteinuria persists beyond 6–12 months, further evaluation (biopsy, advanced imaging) is warranted. **Prevention of Recurrence:** • Emphasize **early treatment of streptococcal infection** (prompt antibiotics for strep throat) to prevent post-streptococcal GN. • Teach **good hygiene** (handwashing, skin care) to prevent streptococcal skin infection (impetigo).

PATHOPHYSIOLOGY: Nephrotic syndrome is a **group of glomerular disorders** characterized by **marked increase in glomerular permeability to protein**, causing **massive urinary protein loss**. The kidney's filtration barrier is damaged (usually by immune-complex deposition, but mechanisms vary by disease type), allowing large proteins (especially albumin) to leak into the urine. As albumin is lost in massive quantities: 1. **Serum albumin concentration drops** (hypoalbuminemia), reducing plasma oncotic pressure. 2. **Fluid shifts from the intravascular space into the tissue spaces** (due to decreased plasma oncotic pressure), causing severe edema. 3. **The liver, detecting decreased plasma protein, responds by synthesizing more albumin AND more lipids** (cholesterol, triglycerides), leading to hyperlipidemia. 4. **Clotting inhibitor proteins (antithrombin III, proteins C and S) are also lost in the urine**, increasing the risk of **thromboembolism** (DVT, pulmonary embolism, renal vein thrombosis). 5. **Immunoglobulin loss** (especially IgG) increases susceptibility to infection. CLINICAL MANIFESTATIONS—THE "NEPHROTIC" TETRAD: The classic presentation is the **four cardinal features**: **1. MASSIVE PROTEINURIA (>3.5 g/day in adults; the DEFINING FEATURE):** • The hallmark and diagnostic criterion for nephrotic syndrome. • Patients often report **foamy, frothy urine** (due to proteinuria foam). • Urine dipstick shows +++/++++ proteinuria. • Urine protein-to-creatinine ratio (UPCR) >3.5 g/g or 24-hour urine protein >3.5 g confirms nephrotic-range proteinuria. **2. HYPOALBUMINEMIA (serum albumin <3.0–3.5 g/dL):** • Results from massive urinary losses exceeding liver synthesis. • Contributes directly to edema formation (decreased plasma oncotic pressure). • Impairs drug binding and increases free (active) drug concentration. **3. GENERALIZED EDEMA — The Most Striking Clinical Feature:** • **Periorbital edema**: puffy, swollen face, especially around the eyes (bilateral and symmetric); often the first thing family notices, saying "the child's face is swollen." • **Dependent edema**: swelling of lower extremities, particularly ankles and feet (worse in ambulatory patients; may spare legs in bedbound patients). • **Sacral/presacral edema**: in bedridden patients (gravity-dependent areas). • **Ascites**: accumulation of fluid in the peritoneal cavity (abdominal distention, fullness, weight gain). • **Anasarca**: severe, generalized body-wide edema affecting face, trunk, genitalia, and extremities. • **Weight gain**: often rapid (1–2 kg/week or more), reflecting fluid/protein accumulation. • Edema is **pitting** (indentation remains after pressing): press the thumb into the shin for 5 seconds; the indentation persists for >2 seconds (pitting edema grade 2–4+). • **Skin tight, shiny appearance** from severe edema; patients may report difficulty putting on clothes, shoes, or rings. **4. HYPERLIPIDEMIA (elevated cholesterol and triglycerides):** • Lipid levels are often markedly elevated (total cholesterol >300 mg/dL, triglycerides >200 mg/dL). • Results from increased hepatic synthesis (compensatory response to protein loss). • Increases risk of **atherosclerotic complications** (premature coronary artery disease, stroke). • Lipiduria may be present (lipid casts and oval fat bodies on UA). **KEY CONTRAST: NEPHRITIC (GLOMERULONEPHRITIS) vs. NEPHROTIC** | Feature | Nephritic (GN) | Nephrotic Syndrome | |---------|----------------|-------------------| | **Proteinuria** | Mild-moderate (<3.5 g/day) | MASSIVE (>3.5 g/day) | | **Hematuria** | PROMINENT (cola-colored urine, RBC casts) | Absent or rare (no gross hematuria) | | **Blood Pressure** | ELEVATED (often significant hypertension) | Normal or LOW | | **Edema** | Mild-moderate (periorbital, face) | SEVERE (generalized, ascites, anasarca) | | **Serum Albumin** | Normal or slightly low | MARKEDLY LOW (<3 g/dL) | | **Lipids** | Normal | ELEVATED (hyperlipidemia) | | **Onset** | Often abrupt (days to weeks) | Often insidious (weeks to months) | | **Cause** | Post-strep infection, IgAN, lupus | Minimal change disease (children), membranous nephropathy (adults), diabetic nephropathy, lupus | **This contrast is high-yield for NLE: nephritic = hematuria + hypertension; nephrotic = massive proteinuria + severe edema + normal/low BP.** COMPLICATIONS OF NEPHROTIC SYNDROME: 1. **THROMBOEMBOLISM (LIFE-THREATENING):** - Loss of anticoagulant proteins (antithrombin III, proteins C and S) in the urine creates a **hypercoagulable state**. - Increased risk of **deep vein thrombosis (DVT)**, **pulmonary embolism (PE)**, and **renal vein thrombosis (RVT)**. - RVT presents as sudden onset of flank pain, hematuria, and potential kidney infarction. - Prophylactic anticoagulation (e.g., warfarin) may be considered for patients with high thrombosis risk (severe hypoalbuminemia, immobility, obesity, antithrombin deficiency). 2. **SEVERE INFECTION:** - Loss of immunoglobulins (especially IgG) + immunosuppressive therapy (steroids) = profound immunosuppression. - Common infections: **bacterial peritonitis** (spontaneous in ascitic fluid—life-threatening), **pneumococcal sepsis**, **meningitis**, **UTI**. - Deaths from infection are among the leading causes of mortality in nephrotic syndrome. - Vaccinations (pneumococcal, meningococcal) are important preventive measures. 3. **ACUTE KIDNEY INJURY:** - Can occur from volume depletion (diuretics used to treat edema), contrast dye, NSAIDs, or disease progression. - Worsening of renal function despite treatment requires evaluation. 4. **MALNUTRITION:** - Massive protein loss, poor appetite, and anorexia from nephrotic syndrome + uremia (if kidney function declines) = inadequate protein/calorie intake. - Must balance: do NOT restrict dietary protein (the body needs protein to replace losses), but also do NOT prescribe excessive protein (does not reduce proteinuria and may worsen uremia). - Current recommendations: **normal-to-modest protein intake** (~0.8–1.0 g/kg/day), NOT the high-protein diets previously recommended. 5. **PROGRESSION TO CHRONIC KIDNEY DISEASE (CKD) / END-STAGE RENAL DISEASE (ESRD):** - Some forms of nephrotic syndrome progress to chronic GN and renal failure; others remit completely. - Prognosis depends on the underlying etiology (minimal change disease in children has excellent prognosis; membranous nephropathy and diabetic nephropathy in adults have more guarded outcomes). ETIOLOGY (Disease Types): Nephrotic syndrome can result from various glomerular diseases: • **Minimal change disease (MCD)**: most common cause in children (~80%); typically steroid-responsive; excellent prognosis. • **Membranous nephropathy**: most common cause in adults (~35%); some are idiopathic, some associated with malignancy, autoimmune disease, or drugs (NSAIDs, ACE inhibitors). • **Focal segmental glomerulosclerosis (FSGS)**: increasingly common; may be primary (idiopathic) or secondary (HIV, heroin, obesity); often steroid-resistant. • **Membranoproliferative glomerulonephritis (MPGN)**: can present with nephrotic or nephritic features. • **Diabetic nephropathy**: leading cause of nephrotic syndrome in developed countries; results from prolonged hyperglycemia. • **Lupus nephritis (LN)**: SLE-related GN; class III (proliferative) or class IV (diffuse proliferative) often presents with nephrotic features. • **Amyloidosis**: AL amyloid or AA amyloid (from chronic inflammation); heart and kidney involvement common. DIAGNOSTIC FINDINGS: • **Urinalysis**: massive proteinuria (+++/++++ on dipstick), lipiduria (oval fat bodies, lipid casts—if visualized, highly suggestive of nephrotic syndrome), may see RBCs if there is concurrent glomerular bleeding, but hematuria is NOT a major feature. • **24-hour urine protein**: >3.5 g/day (confirming nephrotic-range proteinuria). • **Serum albumin**: markedly low (<3.0 g/dL), often <2.5 g/dL. • **Serum lipids**: elevated cholesterol (often >300 mg/dL) and triglycerides. • **Serum creatinine and BUN**: may be normal initially (unless kidney function is already compromised) or elevated (if there is concurrent renal impairment). • **Complement levels**: normal C3 and C4 in most primary nephrotic syndromes; abnormal in lupus or post-streptococcal GN (helps differentiate). • **Kidney biopsy**: often performed to determine the specific underlying disease and guide treatment (especially if diagnosis unclear or if patient is steroid-resistant). Light, immunofluorescence, and electron microscopy provide detailed pathology. NURSING DIAGNOSES (NANDA-I): 1. **Excess fluid volume** related to decreased plasma oncotic pressure from massive proteinuria and hypoalbuminemia, as evidenced by periorbial edema, ascites, weight gain, and pitting edema. 2. **Imbalanced nutrition: less than body requirements** related to proteinuria, poor appetite, and disease process, as evidenced by hypoalbuminemia and muscle wasting. 3. **Risk for infection** related to loss of immunoglobulins in urine and immunosuppressive therapy, as evidenced by immunocompromised state. 4. **Risk for thromboembolism** related to loss of anticoagulant proteins and hypercoagulable state. 5. **Ineffective coping** related to chronic illness burden, body image changes, and dietary restrictions. 6. **Deficient knowledge** related to disease management and treatment. PRIORITY NURSING INTERVENTIONS: **LEVEL 1: PHYSIOLOGIC NEEDS—EDEMA MANAGEMENT, NUTRITION, INFECTION PREVENTION** **Diuretic Therapy & Fluid Management:** • **Loop diuretics** (furosemide/lasix) are first-line: - **Dosing**: typically 40–80 mg IV or PO daily, titrated to urine output and edema response. - **High-dose or IV administration** may be needed for severe edema; maximum effect occurs with IV administration. - Goal: gradual fluid loss of 0.5–1 kg/day (too-rapid diuresis risks acute kidney injury from volume depletion). • **Aldosterone antagonists** (spironolactone 25–50 mg daily): enhance diuresis and reduce potassium loss (loop diuretics cause hypokalemia). • **Fluid restriction**: modest restriction (1.5–2 L/day) during acute edema; as edema resolves, liberalize intake. • **Sodium restriction**: **strict "no added salt" diet (1–2 g/day)** during edema; essential to prevent fluid re-accumulation. Teach patients to avoid: - Canned foods, processed meats, fast food (high sodium) - Adding salt to cooking or at the table - Bouillon cubes, soy sauce, cured meats • Monitor **daily weight at the same time each morning** (after urination, before food); sudden weight gain indicates fluid re-accumulation requiring increased diuretics or stricter fluid/sodium restriction. • Maintain **accurate I&O records**: measure all oral intake and urine output. • Assess **skin integrity** in edematous areas: edematous skin is fragile and prone to breakdown; provide meticulous skin care, elevate limbs when possible, use pressure-relief devices. • Monitor for **signs of dehydration** (with diuretics): orthostatic hypotension, increased BUN/creatinine ratio, decreased urine output. If acute kidney injury develops (worsening creatinine), reduce diuretics and assess for volume depletion. **Nutritional Support:** • **Protein intake**: current evidence suggests **normal protein (0.8–1.0 g/kg/day)**, NOT the high-protein diets previously recommended. High protein intake does NOT reduce proteinuria and may worsen uremic symptoms. • **Adequate calories**: ensure sufficient carbohydrate and fat intake to prevent breakdown of body protein for energy (catabolism). • **Nutrient supplements**: may need to supplement fat-soluble vitamins (A, D, E, K) if proteinuria is severe and malabsorption occurs; iron may be needed if anemic. • **Monitor serum albumin**: gradual improvement expected with therapy; persistent low albumin despite treatment suggests inadequate response or continued massive losses. • Involve dietitian: meal planning, nutrient counseling, and food lists (low-sodium, appropriate protein) are essential. **Infection Prevention (CRITICAL—Major Cause of Morbidity/Mortality):** • **Vaccinations**: administer pneumococcal (PCV13, PPSV23) and meningococcal vaccines before starting steroids or immunosuppressants (antibody response is better before immunosuppression begins); yearly influenza vaccine. • **Avoid live vaccines** if patient is on high-dose steroids or other immunosuppressants. • **Monitor for signs of infection**: fever, cough, dysuria, abdominal pain (peritonitis), or changes in mental status. Report immediately. • **Teach handwashing and hygiene**: especially important before eating, after toileting, and after handling potentially contaminated items. • **Prophylactic antibiotics**: may be considered in some cases (though not routine); specific pathogens (e.g., Streptococcus pneumoniae, Neisseria meningitidis) warrant coverage. • **Avoid invasive procedures** when possible (foley catheters increase UTI/infection risk). **Thromboembolism Prophylaxis:** • **Monitor for signs of DVT/PE**: unilateral leg swelling, calf pain, dyspnea, chest pain, tachycardia. • **Monitor for renal vein thrombosis (RVT)**: sudden flank pain, hematuria, worsening kidney function (oliguria). • **Anticoagulation**: consider prophylactic anticoagulation (e.g., warfarin, target INR 2–3) in high-risk patients: - Severe hypoalbuminemia (albumin <2 g/dL) - Immobility, obesity - Documented thrombotic event - Antithrombin III deficiency • **Mechanical prophylaxis**: sequential compression devices in hospitalized/immobilized patients. • **Encourage early mobilization**: avoid prolonged bed rest to reduce thrombosis risk. **LEVEL 2: SAFETY—MEDICAL MANAGEMENT** **Pharmacologic Therapy (Immunosuppression):** **Corticosteroids (First-Line):** • **Prednisone** (or equivalent) for induction of remission: - **Minimal change disease (children)**: prednisone 1–2 mg/kg/day (max 80 mg) for 4–6 weeks, then slow taper over 2–3 months. **>90% of children achieve remission** with steroids. - **Other forms of nephrotic syndrome**: higher doses or longer courses may be needed; response is more variable. - Expect diuresis and proteinuria improvement within **1–2 weeks** if steroid-responsive. • **Steroid side effects**: moon facies, weight gain, mood changes, hyperglycemia, hypertension, osteoporosis (with prolonged use), increased infection risk, insomnia, GI upset. • **Teach**: Take prednisone in the morning with food; do NOT abruptly stop (risk of acute adrenal insufficiency). Taper must be gradual. **Immunosuppressants (for Steroid-Resistant or Dependent Cases):** • **Cyclophosphamide** (Cytoxan): alkylating agent; used in steroid-resistant minimal change disease or FSGS. IV or PO; risk of hemorrhagic cystitis (ensure high fluid intake), alopecia, myelosuppression. • **Calcineurin inhibitors** (cyclosporine, tacrolimus): slow IL-2 production, reducing T-cell activation. Used in steroid-dependent or steroid-resistant cases. • **Mycophenolate mofetil (MMF)**: antimetabolite; emerging use in membranous nephropathy and other GN. • These agents require careful monitoring of drug levels, renal function, and blood counts. **Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin II Receptor Blockers (ARBs):** • Examples: lisinopril 10 mg daily, losartan 50 mg daily. • **Reduce proteinuria** by dilating the efferent arteriole of the glomerulus, reducing intraglomerular pressure. • **Provide renal protection**: slow progression of kidney disease; prevent glomerular scarring. • **Monitor BP**: these agents may cause mild hypotension (often acceptable, as many nephrotic patients have normal or low BP). • **Monitor K+**: ACEi/ARBs increase K+ reabsorption; check K+ and creatinine at baseline and 1–2 weeks after initiation. **Statins (HMG-CoA Reductase Inhibitors):** • Examples: atorvastatin 40 mg daily, simvastatin 20 mg daily. • Reduce hyperlipidemia, lowering cardiovascular risk. • Continue indefinitely (lipids often normalize with steroid therapy but rebound if steroids are tapered). **NSAIDs: CAUTION/AVOID in Nephrotic Syndrome:** • NSAIDs reduce renal blood flow and can precipitate acute kidney injury, especially if intravascular volume is depleted (from diuretics). • Use only if necessary and with close monitoring; acetaminophen is preferred for pain/fever. **Monitoring Disease Activity:** • Track **urine protein** (24-hour urine protein or spot urine protein-to-creatinine ratio); goal is to reduce proteinuria to <1 g/day (or to <3.5 g/day as a minimum). • Check **serum albumin**: expect gradual improvement toward normal (>3.5 g/dL) with treatment. • Monitor **lipids**: expect decrease with steroid therapy and statin use. • Check **creatinine and BUN** regularly; progressive rise suggests advancing kidney disease. • Assess **BP**: should normalize or remain low (treat if elevated, but avoid over-aggressive lowering if baseline BP is normal). **LEVEL 3: HEALTH RESTORATION—SYMPTOM RESOLUTION & REMISSION** **Expected Timeline for Response:** • **Minimal change disease (children)**: remission (massive proteinuria resolution, normal serum albumin, resolution of edema) within **2–4 weeks** of steroid therapy; ~90% achieve remission. • **Steroid-responsive adults** and **membranous nephropathy**: slower response; may take **2–3 months**. • **Steroid-resistant cases** (especially FSGS): may require alternative immunosuppressants; remission rate is lower (~40–50%). **Monitoring Remission:** • **Complete remission**: urine protein <0.3 g/day (or negative dipstick), normal serum albumin, resolved edema, normal lipids. • **Partial remission**: urine protein <3.5 g/day (nephrotic range eliminated), some improvement in serum albumin and edema. • Proteinuria often **normalizes before edema resolves** (fluid mobilization takes longer). **Relapse Prevention:** • Some patients (especially children with minimal change disease) relapse; relapses are usually **responsive to steroids again**. • Steroid-sparing strategies: use of steroid-sparing agents (cyclophosphamide, calcineurin inhibitors) in frequently relapsing disease. **LEVEL 4: HEALTH PROMOTION—PATIENT & FAMILY EDUCATION** **Understanding Nephrotic Syndrome:** • Explain: "Nephrotic syndrome is a kidney condition where the filtering units leak protein into the urine. Your body is losing too much protein, so fluid builds up in your body, making you swollen. We use medicine (steroids) to reduce the inflammation in your kidneys and help them stop leaking protein." • Explain that steroids are NOT painkillers or anti-inflammatories for arthritis; they reduce kidney inflammation and immune responses. **Medication Adherence:** • **Steroid therapy**: "Take prednisone EXACTLY as prescribed; do NOT adjust the dose or stop abruptly without your doctor's instruction. Taking steroids with food reduces stomach upset. The dose will be gradually reduced (tapered) over weeks to months." • **Do NOT abruptly stop**: abrupt cessation risks adrenal crisis (shock, hypotension, death). • Teach signs of steroid toxicity: excessive weight gain, new-onset diabetes, severe mood changes, or uncontrolled hypertension—report immediately. **Diet (Low-Sodium, Normal Protein, Heart-Healthy):** • "Keep salt intake very low—no more than 1 teaspoon of salt per day (includes salt in processed foods). This helps reduce swelling." • "Eat a normal amount of protein (chicken, fish, beans, eggs, dairy); do NOT eat excessive amounts of protein because it does NOT help the kidneys and may make you feel sick." • "Eat healthy fats (olive oil, nuts); avoid saturated fats and trans fats (fried foods, processed foods) because you have high cholesterol and are at risk for heart disease." • Provide written dietary guidelines and involve a dietitian if available. **Fluid Intake:** • "Limit fluids during the period of active edema (as prescribed); as the swelling improves, you can drink more freely. Ask your doctor about your specific limit." **Activity & Rest:** • "Get up and move around regularly, even if swollen. Movement helps prevent blood clots. Avoid lying in bed for long periods." • "You may feel tired, especially at the beginning; this is normal. Rest when needed, but try to stay active to the extent you can." **Infection Prevention:** • "Wash your hands regularly, especially before eating and after the bathroom. Avoid crowds if possible, and report any signs of infection (fever, cough, painful urination) immediately because your immune system is weakened." • Ensure vaccinations are up to date (pneumococcal, meningococcal, influenza). **Monitoring & Follow-Up:** • "Keep all appointments for blood tests and urine tests. We monitor your kidney function, protein levels, and blood counts to make sure the medicine is working and to adjust doses as needed." • "Weigh yourself daily at the same time (morning, after urination, before breakfast) and keep a log. Sudden weight gain (more than 2–3 pounds in a day) means more fluid is building up; call your doctor." • "Report immediately**: fever, severe swelling that worsens, shortness of breath, chest pain, leg swelling, or inability to urinate (signs of serious complications). **Emotional Support:** • Nephrotic syndrome can be a long illness with ups and downs (relapses); family counseling or support groups can help with coping. • Reassure that many patients, especially children, achieve remission and have excellent long-term outcomes with appropriate treatment.

PATHOPHYSIOLOGY: Urolithiasis is the formation of solid aggregates (calculi/stones) composed of crystalline minerals in the urinary tract. Stones form when urine is supersaturated with stone-forming substances, and the solubility of these substances is exceeded, causing precipitation and crystal formation. Over time, crystals aggregate into larger stones. STONE COMPOSITION (Most-to-Least Common): 1. **Calcium oxalate stones (75–80% of all stones)**: - Calcium and oxalate combine in acidic urine (pH <6.5). - Form in the presence of elevated urine calcium (hypercalcemia, hyperparathyroidism, vitamin D intoxication) or elevated urine oxalate (oxalate-rich diet, inflammatory bowel disease, genetic disorders like hyperoxaluria). - Often accompany increased dietary oxalate (spinach, rhubarb, beets, chocolate, tea, nuts) or calcium. - Risk factors: dehydration, immobility, chronic kidney disease, primary hyperparathyroidism. 2. **Struvite stones (magnesium ammonium phosphate; 10–15% of stones)**: - Form in alkaline urine (pH >7.5), typically secondary to **urinary tract infection** (especially with urease-producing bacteria like Proteus, Klebsiella, Pseudomonas). - Bacteria produce urease enzyme, which splits urea into ammonia and CO2, alkalinizing the urine and promoting precipitation. - **Staghorn stones**: large branched stones that fill the renal pelvis and branch into the major calyces (struvite stones commonly form staghorn configurations); can cause complete obstruction and renal destruction if untreated. - More common in women (due to higher UTI rates). 3. **Uric acid stones (3–5% of stones)**: - Form in acidic urine (pH <5.5). - Associated with gout, chronic diarrhea (intestinal loss of bicarbonate acidifies urine), and high purine diet (organ meats, red meat, shellfish). - Radiolucent on X-ray (cannot see on plain radiographs; visible only on CT). 4. **Cystine stones (1–2% of stones)**: - Result from genetic disorder **cystinuria** (autosomal recessive); kidney cannot reabsorb cystine, so it accumulates in urine and precipitates. - Form in acidic to neutral urine. - Often present in children/young adults. - Radiopaque on X-ray (visible on plain films). RISK FACTORS FOR STONE FORMATION: **Systemic/Metabolic:** • Hyperparathyroidism (elevated PTH, hypercalcemia) • Sarcoidosis (elevated 1,25-vitamin D) • Hyperthyroidism • Immobility (bed rest, paralysis) — increases urinary calcium and decreases citrate (inhibitor of stone formation) • Chronic kidney disease • Recurrent UTI • Cystinuria (genetic) **Urinary/Lifestyle:** • **Dehydration / Low fluid intake** — THE MOST COMMON AND IMPORTANT MODIFIABLE RISK FACTOR • High-sodium diet (increases urinary calcium excretion) • High animal protein diet (increases uric acid and urinary calcium; decreases citrate) • Oxalate-rich diet (spinach, rhubarb, tea, chocolate, nuts) • Urinary retention/incomplete bladder emptying (stasis promotes crystal precipitation) • Anatomic abnormalities (strictures, horseshoe kidney) **Medications:** • Loop diuretics (increase calcium excretion) • Vitamin D supplements (excess leads to hypercalcemia) • Amphotericin B (renal toxicity, creates acidic urine) • Topiramate (increases urinary pH, promotes stone formation) CLINICAL MANIFESTATIONS: **RENAL COLIC — The Acute Presentation (MOST COMMON):** • **Sudden, severe, excruciating flank pain** — often described as "the worst pain of my life" or "worse than childbirth" (extreme severity is characteristic and distinguishes it from other flank pain). • **Unilateral** (one side, the side where the stone is lodged). • **Radiates to the groin, lower abdomen, genitalia, or inner thigh** (follows the path of the ureter as the stone moves downward). • **Restlessness**: unlike patients with peritonitis (who prefer to lie still), patients with renal colic are in constant motion, unable to find a comfortable position. They may roll around, get up and walk, or pace. • **Hematuria**: usually present (from mucosal trauma as the stone scratches the urothelial lining); can be gross (visible blood) or microscopic. • **Nausea and vomiting**: from visceral pain reflex (stone activation of renal/ureteral nerves). • **Urinary symptoms**: dysuria, urgency, frequency (especially if stone is in the lower ureter or urethra). • **Diaphoresis**: profuse sweating from pain and sympathetic activation. • **Fever**: NOT typically present unless infection is concurrent (stone-induced obstruction + infected urine = pyonephrosis/urosepsis — an emergency). **Asymptomatic Discovery:** • Some stones are found incidentally on imaging done for other reasons (patient unaware of stone). • Staghorn stones, in particular, may be asymptomatic until they cause infection or obstruction. DIAGNOSTIC METHODS: **Non-Contrast Helical CT (Gold Standard):** • **CT KUB (kidneys, ureters, bladder)**: non-contrast helical CT is THE gold standard for stone diagnosis. • **Sensitivity: 95–98%** for stones ≥2 mm; detects all stone types (radiopaque and radiolucent). • Shows stone size, location, density (HU = Hounsfield units, helps predict stone composition). • Assesses degree of hydronephrosis and other complications. • Rapidly done (minutes). • Lower radiation than conventional CT but more than plain radiography. **Conventional Imaging (Older, Less Sensitive):** • **Kidney-ureter-bladder (KUB) X-ray** (plain film): - Detects only **radiopaque stones**: calcium oxalate and struvite stones (visible); uric acid and cystine stones may be radiolucent (not visible). - Sensitivity ~60% (misses radiolucent stones). - Useful for follow-up (monitor stone size/progression) but NOT for initial diagnosis. - Cheap and quick. • **Renal ultrasound**: - Shows hydronephrosis (dilated collecting system from obstruction) but NOT the stone itself (stones may be too small or shadowed by bowel gas). - Useful in pregnant patients (avoid radiation); also screens for obstruction. - Sensitivity ~85% for hydronephrosis but <50% for actual stones. **Laboratory Tests:** • **Urinalysis**: hematuria (RBCs, often moderate to heavy); crystals may be present and helpful (calcium oxalate, uric acid, cystine crystals suggest stone type). • **Urine culture**: rule out concurrent UTI (important because stone + infection = pyonephrosis/emergency). • **Serum chemistry**: creatinine and BUN (assess kidney function; elevation suggests obstruction/pre-renal azotemia); calcium, phosphate, uric acid (assess metabolic causes). • **24-hour urine collection** (after acute episode resolves): assess stone-forming risk factors (calcium, oxalate, uric acid, citrate, phosphate, sodium) to guide prevention strategies. **STRAIN ALL URINE:** • **Critical nursing action**: Provide patient with a **strainer, gauze, or filter** and instruct to void INTO the strainer for ALL urine passed during the acute episode. • **Stone recovery** allows laboratory analysis of stone composition (% calcium, oxalate, uric acid, magnesium, etc.), which is **crucial for prevention strategies** (if calcium oxalate, reduce oxalate; if uric acid, use allopurinol). • If stone is passed, save it in a labeled container (do NOT preserve in formalin if analysis is needed soon). NURSING DIAGNOSES (NANDA-I): 1. **Acute pain** related to ureteral obstruction and mucosal trauma from stone movement, as evidenced by severe flank pain, facial grimacing, restlessness, and patient report. 2. **Impaired urinary elimination** related to obstruction/irritation, as evidenced by urinary frequency, urgency, dysuria, and hematuria. 3. **Risk for infection** related to urinary stasis from obstruction. 4. **Risk for acute kidney injury** related to potential bilateral obstruction or unilateral obstruction in a solitary kidney. 5. **Deficient knowledge** related to stone prevention and lifestyle modifications. PRIORITY NURSING INTERVENTIONS (Maslow-Based): **LEVEL 1: PHYSIOLOGIC NEEDS — PAIN MANAGEMENT & FLUID BALANCE (THIS IS THE PRIORITY IN ACUTE RENAL COLIC)** **PAIN RELIEF (Critical and Often URGENT):** Renal colic pain is SEVERE and demands aggressive management. The patient is in genuine distress and suffering; pain relief is the **FIRST priority**, as per Maslow's hierarchy (physiologic pain/comfort is foundational). • **Opioid analgesics** (for severe pain): - **Morphine**: 2–4 mg IV every 2–4 hours (titrate to pain control); alternative: 5–10 mg IM. - **Meperidine (Demerol)**: 50–100 mg IV/IM every 2–4 hours. - **Hydromorphone**: 0.5–2 mg IV every 2–4 hours. - IV opioids are preferred (faster onset, better titration) for severe renal colic; IM or PO in less acute settings. - Goal: reduce pain to a tolerable level (patient may not achieve complete pain-free state immediately; aim for 5–6/10 pain scale). - Monitor respiratory depression, hypotension, and altered mental status with opioids. • **NSAIDs** (excellent adjunct; reduce pain AND ureteral spasm): - **Ketorolac (Toradol)**: 30 mg IV/IM every 6 hours (max 5 days) — particularly effective for renal colic because it reduces prostaglandins that mediate inflammation and spasm in the ureter. - **Indomethacin**: 50 mg rectal suppository (sometimes used in ED settings when IV access is unavailable). - NSAIDs may be **AS effective as opioids** for acute renal colic; some studies show opioid + NSAID combination is superior to either alone. - **Caution**: avoid NSAIDs if kidney function is already impaired (high creatinine) or if patient is significantly dehydrated (pre-renal status); NSAIDs reduce renal blood flow. • **Antispasmodics** (adjunct to reduce ureteral cramping): - **Hyoscyamine (Levsinex)**: 0.125–0.25 mg PO/SL every 4–6 hours; reduces smooth-muscle spasm in the ureter. - Less evidence than NSAIDs/opioids but provides additional relief. • **Heat therapy** (non-pharmacologic adjunct): - Heating pad to the flank provides some comfort; warmth may relax ureteral spasm. - Patient may find relief in positioning (standing, walking, pacing). **Fluid Management:** • **Increase fluid intake to 2.5–3 L/day** (or higher, if tolerated, to maintain high urine output and flush the stone). • Start **IV hydration** if patient is unable to tolerate oral fluids (vomiting from pain/nausea): - **Normal saline (0.9% NS)** or **Lactated Ringer's (LR)** at 1–1.5 mL/min (to achieve urine output ~200 mL/hour) to promote stone passage. - Goal: maintain urine output ≥200 mL/hour (high urine flow facilitates passage of small stones and reduces crystallization). • Monitor **I&O carefully**: measure all fluids in and all urine output (volume, color). Decreased urine output on one side (if having unilateral obstruction) is an **ominous sign** (suggests non-functioning kidney from complete obstruction). **Anti-emetics:** • **Metoclopramide (Reglan)**: 10 mg IV/IM every 6 hours; reduces nausea/vomiting. • **Ondansetron (Zofran)**: 4–8 mg IV every 8 hours; alternative if metoclopramide is ineffective. • Nausea/vomiting can prevent oral fluid intake; managing it is important to maintain hydration. **LEVEL 2: SAFETY — COMPLICATION MONITORING (WATCHFOR EMERGENCY SITUATIONS)** **Monitor for Obstruction & Infection (Medical Emergency):** The combination of **obstruction + infection = pyonephrosis/urosepsis**, a true urologic emergency requiring immediate decompression (percutaneous nephrostomy or stent). **Red flags requiring IMMEDIATE physician notification and possible emergency intervention:** • **Fever (38.5°C or higher) + flank pain + decreased urine output** = suspicion of infected obstructed kidney (pyonephrosis). This is an emergency. • **Hypotension, tachycardia, altered mental status, lactate elevation** = septic shock from infected obstruction. ICU-level care needed. • **Anuria (no urine output for several hours) from one kidney** = complete obstruction; if patient has a solitary kidney, this can rapidly progress to acute kidney injury. • **Worsening renal function** (creatinine, BUN rising rapidly) = pre-renal azotemia from obstruction or acute kidney injury. Assessment: • Monitor **temperature every 2–4 hours**; fever + obstruction is a surgical emergency. • Monitor **vital signs**: tachycardia, hypotension, or worsening vital sign trends suggest sepsis. • Monitor **urine output**: measure hourly during acute phase; assess for anuria or oliguria. If obstruction is complete and patient is developing signs of urosepsis, urologic intervention (stent, nephrostomy) must be done emergently. • Monitor **serum creatinine and BUN**: rising values suggest obstruction-induced kidney dysfunction; trend these tests. **Stone Passage Monitoring:** • Most small stones (<5 mm) pass spontaneously within 48 hours; stones 5–10 mm pass in 50% of cases; stones >10 mm rarely pass spontaneously (often require intervention). • **Expectant management** (observation with pain control and hydration) is reasonable for small stones; if stone has not passed in **4–6 weeks**, intervention is typically pursued. • Assess for **evidence of stone passage**: hematuria should resolve, flank pain should improve, and if straining urine, stone may be recovered. **LEVEL 3: HEALTH RESTORATION — STONE PASSAGE & SYMPTOM RESOLUTION** **Interventions to Facilitate Passage:** • **Ambulation/movement**: encourage patient to walk, move, and change position; movement facilitates stone passage through the ureter. • **Continued high fluid intake**: 2.5–3 L/day ongoing. • **Alpha-blockers** (may facilitate passage): **tamsulosin (Flomax) 0.4 mg daily**; relaxes smooth muscle in the lower ureter and increases stone passage rates (particularly for lower-ureteral stones). This is an optional adjunct. **Procedures for Stones Not Passing Spontaneously:** • **Extracorporeal shock wave lithotripsy (ESWL)**: - Shock waves are focused on the stone, fragmenting it into smaller pieces that can be passed more easily. - Noninvasive, outpatient procedure; effective for stones <2 cm. - **Post-ESWL effects**: expect increased hematuria (can be gross), flank pain, and possible "steinstrasse" (street of stones — fragments block the ureter). - Contraindications: pregnancy, uncorrected bleeding disorders, active UTI (treat infection before ESWL). • **Ureteroscopy (URS) with basket extraction or laser lithotripsy**: - Endoscopic procedure: a thin scope (ureteroscope) is passed through the urethra and bladder up the ureter. - Stone is visualized, trapped in a basket, and removed OR fragmented with laser (holmium laser) and fragments removed. - Effective for stones in the lower/middle ureter; good for larger stones or those not amenable to ESWL. - Risks: ureteral perforation, infection, stricture formation. • **Percutaneous nephrolithotomy (PCNL)**: - Surgical procedure: a small tube is placed through the skin directly into the kidney (percutaneous access); stone is visualized and fragmented with laser or pneumatic lithotriptor. - Reserved for **large stones** (>2 cm), **staghorn stones**, or **failed ESWL/URS**. - Invasive; higher morbidity than URS/ESWL but higher efficacy for large/complex stones. - Allows stone-free rate >90%. • **Urinary stent placement** (ureteral stent): - Thin plastic tube placed in the ureter to maintain patency and allow urine to drain around the obstruction. - Used when stone is obstructing and causing pain/azotemia but patient is not yet ready for definitive removal (e.g., pregnancy, acute infection to be treated first). - Allows hydronephrosis to resolve and kidney function to stabilize while awaiting procedure. - Stent placement is temporary (removed after definitive stone therapy or spontaneous passage). - Stents can cause pain, UTI, and encrustation if left in place too long. **Post-Procedure Management (ESWL, URS, PCNL):** • **Expect hematuria and flank pain** for several days; these are normal. • Maintain **high fluid intake** (2.5–3 L/day) to flush stone fragments and prevent secondary stone formation. • Monitor **urine output** and **pain**; report sudden fever, worsening pain, or anuria (possible complications: infection, ureteral perforation, complete obstruction from fragments). • Follow-up imaging (KUB, ultrasound, or CT) to confirm stone clearance. **LEVEL 4: HEALTH PROMOTION — PREVENTION OF RECURRENCE (Most Important Long-Term Intervention)** Approximately **50% of patients with one kidney stone will form another within 5–10 years**, making prevention essential. Prevention strategies are based on stone type and identified risk factors. **Universal Prevention (For ALL Stone Patients):** • **HIGH FLUID INTAKE — THE SINGLE MOST IMPORTANT PREVENTIVE MEASURE**: - Goal: **2.5–3 L of fluid per day** (some sources recommend even higher, up to 3.5–4 L/day). - Target **urine output >2 L/day** (dilute urine reduces solute concentration and prevents crystal precipitation). - Encourage **water as the primary beverage**; some evidence supports citrus juices (contain citrate, an inhibitor of stone formation). - Avoid excessive caffeine and alcohol (diuretic effect, increases dehydration risk). - Educate on **signs of dehydration**: pale, concentrated (dark) urine (goal is pale, dilute urine). - **Compliance is the biggest challenge**; reinforce this at every visit. **Stone-Specific Prevention Strategies:** **For Calcium Oxalate Stones (Most Common):** • **Dietary oxalate restriction**: limit oxalate-rich foods: - **Spinach, rhubarb, beets** (highest oxalate) - **Chocolate, tea, nuts, seeds** (high oxalate) - **Moderate oxalate foods**: wheat bran, beans, raspberries - Patient should not ELIMINATE oxalate (some is dietary, some is endogenous); instead, **moderate intake**. • **Calcium intake**: do NOT restrict dietary calcium (as previously recommended). Adequate calcium (1000–1200 mg/day) is protective because **dietary calcium binds oxalate in the GI tract, preventing absorption** (paradoxically, HIGH dietary calcium reduces stone risk). Instead, ensure normal calcium intake. • **Low sodium diet** (1500–2300 mg sodium/day): high sodium increases urinary calcium; reducing salt reduces stone recurrence. • **Moderate protein intake** (0.8–1.2 g/kg/day): high protein diet increases uric acid and urinary calcium. • **Weight loss** (if overweight/obese): obesity increases stone risk. • **Pharmacologic** (if dietary measures insufficient): - **Thiazide diuretic** (hydrochlorothiazide 25 mg daily): reduces urinary calcium; reduces stone recurrence by ~50% in hypercalciuric patients. - **Potassium citrate**: increases urine citrate (inhibitor of stone formation); dose adjusted based on serum K+ and urine citrate. - **Allopurinol** (if hyperuricemia/high uric acid on 24-hour urine): reduces uric acid production, decreasing stone formation. **For Struvite Stones (Infection-Associated):** • **Treat and prevent UTI**: struvite stones are directly caused by UTI; eradicating infection is the primary prevention. - Complete antibiotic courses; obtain post-treatment urine culture to confirm eradication. - Long-term prophylactic antibiotics (e.g., nitrofurantoin 100 mg daily) may be needed to prevent recurrent UTI and stone formation. - In some cases, if staghorn stone is present and complete surgical removal is not feasible, **long-term suppressive antibiotics** are used to prevent superimposed infection. • **Urease inhibitor** (acetohydroxamic acid): rarely used; inhibits urease and theoretically slows stone growth, but limited evidence and GI side effects limit use. **For Uric Acid Stones:** • **Low-purine diet**: limit organ meats (liver, kidney), red meat, shellfish, anchovies, sardines. • **Alkalinize urine**: keep urine pH >6.5 to promote uric acid solubility. **Potassium citrate** (2–3 mEq/kg/day, target urine pH 6.5–7.0) is the main strategy. • **Allopurinol**: reduces uric acid production; 100–300 mg daily, dose adjusted to maintain serum uric acid <6 mg/dL. • **Weight loss** (if obese): obesity worsens gout and uric acid stones. • **Avoid dehydration**: low urine volume concentrates uric acid. **For Cystine Stones (Cystinuria):** • **Very high fluid intake**: >3–4 L/day (higher than for other stone types). • **Alkalize urine**: **potassium citrate** to keep urine pH >7.5 (cystine is more soluble in alkaline urine). • **Low-sodium diet** (restricting sodium reduces cystine excretion). • **Limit protein** (reduces cystine production). • **Pharmacologic**: - **D-penicillamine**: binds to cystine, forming soluble disulfide complex; 250–500 mg 2–4 times daily. Side effects limit use (rash, fever, GI upset). - **Tiopronin**: similar mechanism to penicillamine; alternative if penicillamine not tolerated. **PATIENT EDUCATION — PREVENTION TEACHING (LONG-TERM):** • **Fluid intake is KEY**: "Drink plenty of water every day—at least 8–10 glasses. The more you drink, the less likely your urine will form another stone. Aim to keep your urine pale and dilute." • **Diet**: - "If your stone was calcium oxalate, limit spinach, chocolate, and nuts, but do NOT avoid calcium." - "Keep salt intake low—salt increases calcium loss in your urine." - "Eat a normal amount of protein, not excessive amounts." - "If your stone was uric acid, avoid organ meats and red meat, and keep your weight healthy." • **Follow-up**: "Have your 24-hour urine tested after your stone passes. This helps us understand what kind of stone you make and how to prevent the next one. Keep all follow-up appointments." • **Red flags**: "Report fever, severe flank pain, or inability to urinate—these could mean another stone is forming or your kidney is infected." • **Medications**: "If prescribed, take your prevention medicine (thiazide, allopurinol, citrate) even when you have no symptoms. Consistency matters." **Straining Urine at Home:** • Provide **strainer or gauze filter** at discharge. • "For the next week, strain all your urine into this strainer when you go to the bathroom. If you see any stone fragments or gravel, save them in a small container and bring them to your next appointment for analysis." • Explain that stone analysis guides long-term prevention.